CANDEL THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 21.52K shares, a 76.81% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 10.94K shares, a 90.76% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 2.45K shares, a 97.88% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 6.22K shares, a 86.57% decline year-over-year.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 219.81K shares, a 74.05% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 846.94K shares.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 352.58K shares, a 1344.39% increase from fiscal 2021.
- CANDEL THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 24.41K shares, a 14.28% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 21.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 41.13K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 10.94K shares 10-Q · filed 2026-05-14 | 112.39K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 2.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 219.81K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 6.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 333.13K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 92.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 373.21K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 118.36K shares 10-Q · filed 2025-05-13 | 818.34K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 115.77K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 846.94K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 46.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2024-06-30 | 537.91K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | |
| 2024-03-31 | 146.96K shares 10-Q · filed 2024-05-14 | |
| 2022-12-31 | 27.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 352.58K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 324.68K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 321.37K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | 324.68K shares derived: sum of 4 quarters · filed 2022-08-05 |
| 2022-03-31 | 3.31K shares 10-Q · filed 2022-05-12 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 24.41K shares 10-K · filed 2022-03-29 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2020-12-31 | 21.36K shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |